Smith & Nephew SNATS, Inc. $SNN Shares Sold by Highland Capital Management LLC

Highland Capital Management LLC reduced its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 2.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,835 shares of the medical equipment provider’s stock after selling 540 shares during the quarter. Highland Capital Management LLC’s holdings in Smith & Nephew SNATS were worth $608,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Bessemer Group Inc. boosted its stake in shares of Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 1,701 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in Smith & Nephew SNATS during the first quarter worth $211,000. GAMMA Investing LLC boosted its position in Smith & Nephew SNATS by 22.4% during the first quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider’s stock worth $103,000 after purchasing an additional 666 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in Smith & Nephew SNATS by 37.7% in the first quarter. Oppenheimer Asset Management Inc. now owns 53,590 shares of the medical equipment provider’s stock valued at $1,520,000 after purchasing an additional 14,677 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Smith & Nephew SNATS in the first quarter valued at $335,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SNN has been the subject of several research reports. Canaccord Genuity Group lifted their price target on Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday, August 18th. Wall Street Zen cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Friday. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Saturday, September 27th. Seven research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $36.00.

Smith & Nephew SNATS Stock Performance

Shares of NYSE SNN opened at $36.34 on Monday. The company has a 50-day simple moving average of $36.16 and a 200-day simple moving average of $31.23. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The company has a market cap of $15.83 billion, a PE ratio of 16.83, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. Smith & Nephew SNATS, Inc. has a 12 month low of $23.69 and a 12 month high of $38.79.

Smith & Nephew SNATS Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be paid a dividend of $0.285 per share. This represents a dividend yield of 165.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS’s dividend payout ratio is currently 26.39%.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.